Clinical Trials Browser

Docetaxel × Genitourinary × Clear all

NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Phase 2 Active not recruiting

47 enrolled 16 charts

Hormone Sensitive Prostate Cancer

NCT04633252 2026-05-27

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Phase 3 Recruiting

Prostatic Neoplasms

NCT06524544 2026-05-27

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT06353386 2026-05-26

MK-5684-01A

Phase 1/2 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms, Castration-Resistant

NCT06545955 2026-05-22

ABLE-22

Phase 3 Recruiting

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT06925737 2026-05-22

MK-2400-001

Phase 3 Recruiting

Prostatic Neoplasms

NCT07213674 2026-05-22

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT07419295 2026-05-22

TroFuse-031

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT06661122 2026-05-19

HAYATE

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07316686 2026-05-18

Lutécio

Phase 1 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT00183937 2026-05-15

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

Phase 2 Terminated

15 enrolled 11 charts

Prostatic Neoplasms

NCT06863272 2026-05-15

IDeate-Prostate02

Phase 1/2 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07590934 2026-05-15

PROSPECTOR

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT03574571 2026-05-14

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04579224 2026-05-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03390504 2026-05-11

THOR

Phase 3 Active not recruiting

629 enrolled 32 charts

Urothelial Cancer

NCT06929286 2026-05-11

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07225946 2026-05-11

KLK2-PASenger

Phase 3 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT05818683 2026-05-08

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Phase 1 Recruiting

Metastatic Castration-resistant Prostate Neoplasms

NCT06931340 2026-05-08

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT03070886 2026-05-07

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Phase 2/3 Completed

Stage I Prostate Adenocarcinoma AJCC v7

NCT06764485 2026-05-06

rechARge

Phase 3 Recruiting

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07287150 2026-05-06

InavoPC

Phase 2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT05005728 2026-05-05

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT05538663 2026-05-05

BRIDGE

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06551324 2026-05-05

MEVPRO-1

Phase 3 Active not recruiting

Prostatic Neoplasms, Recurrence

NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Phase 3 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT02649855 2026-04-29

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

Phase 2 Completed

74 enrolled 15 charts

Prostatic Neoplasms

NCT03218826 2026-04-29

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Completed

23 enrolled 15 charts

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03517969 2026-04-23

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

73 enrolled 14 charts

Prostatic Neoplasms

NCT02913196 2026-04-20

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

Phase 1 Completed

Prostate Cancer Metastatic

NCT06857175 2026-04-20

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT07322263 2026-04-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT06439225 2026-04-16

OPTION-DDR

Phase 3 Recruiting

Prostatic Neoplasms

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06615752 2026-04-15

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

Phase 3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT04895709 2026-04-13

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06392841 2026-04-08

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07344779 2026-04-03

ROAD

Active not recruiting

Prostatic Neoplasms

NCT02044354 2026-04-01

CABA-DOC

Phase 3 Completed

Metastatic Castration-resistant Prostate Cancer

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04663997 2026-03-27

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06282588 2026-03-19

THUNDER

Phase 2/3 Recruiting

Prostatic Neoplasms

NCT07428642 2026-03-18

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Prostatic Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms